JPMorgan analyst Rachel Vatnsdal reiterated an Underweight rating and $20.00 price target on Myriad Genetics (NASDAQ: MYGN).The analyst comments "Earlier ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE